Expand BEAM Menu
BEAM MENU

BEAM Stock Summary and Trading Ideas (Beam Therapeutics | NASDAQ:BEAM)

Charts for Today's Stock Price and Implied Volatility in Beam Therapeutics

Stock Price & Volume | Full Chart

30-Day Implied Volatility | IV30 Full Chart

Trade Ideas for Best Option Strategies for BEAM by Theoretical Edge and Win Rates

Sentiment

News

How Peter Marks' FDA departure is impacting pharma, biotech stocks

Seeking Alpha News (Mon, 31-Mar 12:37 PM ET)

Beam Therapeutics Announces Pricing of Underwritten Offering

Globe Newswire (Mon, 10-Mar 6:01 AM ET)

Trading Statistics

Key Ratios

Beam Therapeutics (BEAM) Frequently Asked Questions

What does Beam Therapeutics do?

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

What symbol and exchange does Beam Therapeutics shares trade?

Beam Therapeutics trades on the NASDAQ stock market under the symbol BEAM.

What is Beam Therapeutics stock price doing today?

As of April 2, 2025, BEAM stock price climbed to $18.96 with 1,071,467 million shares trading.

What is Beam Therapeutics's Beta?

BEAM has a beta of 1.94, meaning it tends to be more sensitive to market movements. BEAM has a correlation of 0.14 to the broad based SPY ETF.

How much is Beam Therapeutics worth?

BEAM has a market cap of $1.89 billion. This is considered a Small Cap stock.

How much money does Beam Therapeutics make?

Last quarter Beam Therapeutics reported $30 million in Revenue and -$1.09 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $.19.

What is the highest and lowest price Beam Therapeutics traded in the last 3 year period?

In the last 3 years, BEAM traded as high as $73.27 and as low as $16.95.

What are the top ETFs holding Beam Therapeutics?

The top ETF exchange traded funds that BEAM belongs to (by Net Assets): ARKK, VTI, VB, IWM, ARKG.

Is Beam Therapeutics (BEAM) a good investment?

BEAM has underperformed the market in the last year with a price return of -41.9% while the SPY ETF gained +9.9%. BEAM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.5% and -16.1%, respectively, while the SPY returned -3.1% and +1.3%, respectively.

What are the support and resistance levels for Beam Therapeutics (BEAM)?

BEAM support price is $16.62 and resistance is $18.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BEAM shares will trade within this expected range on the day.